X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7136) 7136
Newspaper Article (502) 502
Magazine Article (79) 79
Newsletter (55) 55
Book Chapter (31) 31
Government Document (15) 15
Trade Publication Article (14) 14
Transcript (14) 14
Publication (11) 11
Book / eBook (10) 10
Conference Proceeding (5) 5
Web Resource (4) 4
Dissertation (3) 3
Book Review (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5058) 5058
female (3117) 3117
oncology (2946) 2946
male (2529) 2529
middle aged (2233) 2233
chemotherapy (2202) 2202
adult (1918) 1918
cancer (1910) 1910
maintenance (1854) 1854
aged (1820) 1820
maintenance therapy (1521) 1521
maintenance chemotherapy (1483) 1483
treatment outcome (1371) 1371
hematology (1220) 1220
antineoplastic combined chemotherapy protocols - therapeutic use (1136) 1136
care and treatment (1000) 1000
therapy (890) 890
survival (788) 788
health maintenance organizations (763) 763
analysis (731) 731
aged, 80 and over (702) 702
patients (685) 685
research (666) 666
disease-free survival (650) 650
prognosis (642) 642
adolescent (609) 609
antineoplastic agents - therapeutic use (578) 578
retrospective studies (561) 561
cancer therapies (543) 543
animals (533) 533
medicine & public health (533) 533
clinical trials (532) 532
double-blind (532) 532
health aspects (520) 520
breast cancer (509) 509
ovarian cancer (504) 504
tumors (498) 498
remission induction (496) 496
young adult (489) 489
pharmacology & pharmacy (480) 480
stem cells (478) 478
trial (478) 478
drug therapy (470) 470
open-label (457) 457
transplantation (452) 452
multiple myeloma (436) 436
risk factors (433) 433
antineoplastic combined chemotherapy protocols - adverse effects (423) 423
quality of life (423) 423
child (415) 415
survival analysis (415) 415
follow-up studies (409) 409
hematology, oncology and palliative medicine (409) 409
bevacizumab (397) 397
mutation (394) 394
neoplasm staging (390) 390
recurrence (389) 389
lung neoplasms - drug therapy (382) 382
stem-cell transplantation (381) 381
maintenance chemotherapy - methods (377) 377
medicine, general & internal (376) 376
metastasis (371) 371
rituximab (369) 369
immunotherapy (363) 363
studies (354) 354
induction chemotherapy (346) 346
abridged index medicus (345) 345
medical research (344) 344
drug administration schedule (342) 342
lung cancer (333) 333
survival rate (333) 333
time factors (330) 330
expression (327) 327
leukemia (325) 325
prospective studies (320) 320
multiple myeloma - drug therapy (313) 313
combined modality therapy (307) 307
risk (299) 299
gastroenterology & hepatology (294) 294
medicine (292) 292
carcinoma, non-small-cell lung - drug therapy (289) 289
randomized controlled trials as topic (288) 288
randomized-trial (287) 287
diagnosis (285) 285
surgery (284) 284
multicenter (282) 282
quality-of-life (282) 282
toxicity (282) 282
immunology (281) 281
carcinoma (279) 279
relapse (277) 277
efficacy (275) 275
proteins (275) 275
cyclophosphamide (272) 272
children (271) 271
bortezomib (270) 270
phase-iii trial (269) 269
cisplatin (268) 268
review (266) 266
management (262) 262
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7698) 7698
French (87) 87
German (48) 48
Japanese (35) 35
Spanish (27) 27
Russian (15) 15
Chinese (14) 14
Portuguese (14) 14
Polish (9) 9
Korean (6) 6
Italian (5) 5
Czech (4) 4
Croatian (1) 1
Hungarian (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2016, Volume 34, Issue 25, pp. 2969 - 2979
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
.... The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
British journal of haematology, ISSN 0007-1048, 2014, Volume 167, Issue 3, pp. 394 - 401
...) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS... 
Burkitt leukaemia | children | chemotherapy | rituximab | Burkitt lymphoma | Rituximab | Chemotherapy | Children | ACUTE-LYMPHOBLASTIC-LEUKEMIA | PLUS RITUXIMAB | PHASE-II | RISK | ADULT BURKITT | B-CELL LYMPHOMA | CODOX-M/IVAC | THERAPY | NON-HODGKINS-LYMPHOMA | INTERMEDIATE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Burkitt Leukaemia | Burkitt Lymphoma | adolescents
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 25, pp. 2403 - 2415
The addition of veliparib, a PARP inhibitor, to induction chemotherapy and maintenance therapy in women with advanced ovarian cancer significantly improved progression-free survival over induction... 
OLAPARIB | MEDICINE, GENERAL & INTERNAL | PRIMARY SURGERY | PRIMARY PERITONEAL CANCER | DOUBLE-BLIND | PLATINUM | FALLOPIAN-TUBE | OPEN-LABEL | PHASE-2 | EPITHELIAL OVARIAN | PARP INHIBITOR VELIPARIB | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Ovarian Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Benzimidazoles - adverse effects | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Benzimidazoles - therapeutic use | Double-Blind Method | Administration, Oral | Carboplatin - administration & dosage | Combined Modality Therapy | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Cystadenocarcinoma, Serous - surgery | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Intention to Treat Analysis | Quality of Life | Aged | Mutation | Ovarian Neoplasms - surgery | Chemotherapy, Combination | Enzyme inhibitors | Drug therapy | Patient outcomes | Ovarian cancer | Testing | Thrombocytopenia | Adenosine | Statistical analysis | Ovarian carcinoma | Homologous recombination | Nausea | Breast cancer | Cancer therapies | Survival | Patients | Chemotherapy | Ribose | Surgery | Paclitaxel | Carboplatin | Population | Tumors
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 108, pp. 232 - 237
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
.... We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
European Urology, ISSN 0302-2838, 2007, Volume 52, Issue 4, pp. 1123 - 1130
Journal Article